Transitioning from doctoral research into industry drug discovery requires translating rigorous scientific inquiry into robust, high-throughput workflows. At Genentech, I developed automated ELISA and qPCR screening protocols on Tecan robotic workstations, accelerating lead candidate profiling schedules by three weeks. My transition from academic discovery to biopharmaceutical assay development stems from a deliberate commitment to scalable therapeutic validation. Aetheris Therapeutics represents the ideal environment to deploy my experience in microfluidics and mass spectrometry toward accelerating your pipeline of novel targeted therapies.
During my time at Genentech, I focused on optimizing high-dimensional assay platforms for complex biological matrices. By refining analytical methods using HPLC/LC-MS and multi-color flow cytometry, I increased signal-to-noise ratios by 40 percent across primary cellular assays. I also designed microfluidic chip protocols that reduced sample input volume requirements by half, enabling comprehensive profiling of rare cell populations. My systematic approach to assay optimization ensures that downstream screening pipelines generate reproducible data while minimizing reagent consumption and overall experiment turnaround times.
Aetheris Therapeutics stands out for its pioneering work in engineered cellular therapies and innovative target validation platforms. Your team's emphasis on high-throughput microfluidic screening closely matches my experience in integrating Tecan robotic automation with LC-MS quantitative readouts. Having spent my academic career mastering mechanistically complex biological assays and applying them at Genentech, I understand the precision required to move early-stage candidates into formal development. I am eager to apply this technical rigor to support your expanding analytical operations and upcoming pipeline milestones.
I welcome the opportunity to discuss how my assay optimization background and hands-on experience with automated platform technologies can add immediate value to your research group. Developing high-precision assays that bridge fundamental discovery with scalable industry standards remains my core professional focus. I look forward to exploring how my background in flow cytometry, mass spectrometry, and assay automation aligns with the goals of Aetheris Therapeutics. Thank you for your time and consideration of my application.
Best regards,
Yuki Tanaka